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The aim was to compare the short and long-term effects of subthalamic nucleus
(STN) deep brain stimulation (DBS) on gait dysfunction and other cardinal symptoms of
Parkinson’s disease (PD). Two groups of patients were studied. The first group (short-term
DBS, n = 8) included patients recently implanted with STN DBS (mean time since DBS
15.8 months, mean age 58.8 years, PD duration 13 years); the second group (long-term
DBS, n = 10) included patients with at least 5 years of DBS therapy (mean time since
DBS 67.6 months, mean age 61.7 years, PD duration 17.1 years). Both groups were
examined using the Unified Parkinson’s Disease Rating Scale (UPDRS) and Gait and
Balance scale (GABS) during four stimulation/medication states (ON/OFF; OFF/OFF;
OFF/ON; ON/ON). Data were analyzed using repeated measures ANOVA with time since
implantation (years) between groups and medication or DBS effect (ON, OFF) within
groups. In the short-term DBS group, stimulation improved all UPDRS subscores similar
to dopaminergic medications. In particular, average gait improvement was over 40%
(p = 0.01), as measured by the UPDRS item 29 and GABS II. In the long-term DBS
group, stimulation consistently improved all clinical subscores with the exception of gait
and postural instability. In these patients, the effect of levodopa on gait was partially
preserved. Short-term improvement of gait abnormalities appears to significantly decline
after 5 years of STN DBS in PD patients, while effectiveness for other symptoms remains
stable. Progressive non-dopaminergic (non-DBS responsive) mechanisms or deleterious
effects of high frequency STN stimulation on gait function may play a role.
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INTRODUCTION
Deep brain stimulation (DBS) is a successful treatment for advanced Parkinson’s disease (PD)
complicated by fluctuations of response to levodopa and/or levodopa-induced dyskinesias.
Long-term (up to 11 years) benefits of subthalamic nucleus (STN) DBS have been reported
for tremor, rigidity, bradykinesia, and motor fluctuations (1–6); however, the long-term
effects on gait abnormalities, which are among the most disabling symptoms of advanced
PD, are a matter of controversy (7). A large meta-analysis documented the short-term
benefits (up to 2 years) of both STN and GPi stimulation on parkinsonian gait (8, 9), a
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finding that was confirmed using more detailed analyses of gait
parameters (10–15) and balance control (14, 16–19).
Unfortunately, the short-term benefits of DBS on
parkinsonian gait and postural abnormalities appear to
decline over time (1, 3–6, 20–24). Gradual gait deterioration
in PD patients after chronic DBS is usually attributed to the
natural progression of the disease, but the cause may also be
attributed to a decreasing beneficial effect or even a negative
effect of long-term stimulation specifically on gait. Indeed, gait
worsening is considered by some authors as a complication of
chronic DBS therapy (14, 25).
The purpose of this study was to measure the short- and
long-term effects of STN DBS on the cardinal symptoms of PD
(i.e., tremor, bradykinesia, rigidity) in comparison to gait and
postural abnormalities.We hypothesized that, if the deterioration
of DBS benefits is due to the natural generalized progression of
the disease, the response to DBS of all motor symptoms should
show similar degrees of worsening over time. In other words,
despite the predictable worsening of the OFF medication scores
caused by disease progression, the positive effects of DBS should
remain proportionally similar over time among various measures
of motor function. In contrast, if the response to stimulation of
only some symptoms deteriorates over time, then more complex
explanations than simple disease progression might be required.
MATERIALS AND METHODS
Study Subjects
We prospectively enrolled 18 consecutive PD patients attending
the Movement Disorders Center. All of them previously
underwent bilateral STN DBS implantation with the same
surgeon (RA). Patients enrolled in the study were divided into
two groups based on the duration of DBS treatment. A short-term
group included eight patients (mean age 59, SD 4.6 years; disease
duration 13, SD 4.6 years; duration of the disease at the time of
stimulation 11, SD 5 years) with postoperative follow-up ranging
between 1 and 2 years (mean 16, SD 7 months). A long-term
group included 10 subjects (mean age 62, SD 10 years; disease
duration 17, SD 5.1 years; duration of the disease at the time of
stimulation 11.4 SD 5.4 years) who had received STN stimulation
for∼5 years (mean 68, SD 14 months).
Clinical Evaluations
The Unified Parkinson’s Disease Rating Scale (UPDRS) and the
Gait and Balance Scale (GABS) were used to assess symptom
severity. GABS, which is designed to assess gait, freezing of
gait, balance, and posture, consists of three parts: GABS I:
historical information; GABS II: measurement of 14 gait and
balance parameters and timed items; and GABS III: including
time to cover 14m walking at a preselected speed, time to walk
as quickly as possible, and time to perform the stand-walk-sit
test (SWS) (26). Examinations were evaluated and compared for
the two study groups. One investigator (HB) performed all of
the evaluations, utilizing videotaped patient examinations. Each
patient was initially evaluated in the OFFmedication state (i.e., at
least 12 h following the last dose of levodopa) with the stimulators
on (ON stim/OFF med). Stimulation was then discontinued
for at least 30min so that patients could be evaluated in the
OFF stim/OFF med state. Subsequently, the patients took their
usual morning medication dose and were examined a third time
in the OFF stimulation/ON medication (OFF stim/ON med)
state. Finally, patients were evaluated in the ON/ON condition
30–60min after switching DBS back on to their individualized
therapeutic settings.
The effects of stimulation were assessed by comparing the
UPDRS-III and GABS scores in the ON stim/OFFmed condition
to those in the OFF/OFF condition. The ON medication
conditions were also analyzed to test the effects of the
dopaminergic medications. In addition to the total UPDRS-
III and GABS scores, specific subscores for tremor, rigidity,
bradykinesia, gait, and postural instability and gait disorders
(PIGD) were evaluated independently.
The study was performed in accordance with the declaration
of Helsinki and approved by the local institutional review board.
Informed consent was obtained from each patient.
Statistical Analysis
We used a repeated-measures analysis of variance (ANOVA) for
intergroup comparisons, employing the number of years after
DBS (1 and 5) as the intergroup fixed factor. The medication
(ON, OFF) and stimulation status (ON, OFF) were intragroup
fixed factors. The Tukey–Kramer multiple comparison post-hoc
test was used to assess statistical significance. For an easy-to-
survey expression of improvement in each of the symptoms with
patients in the ON and OFF drug condition, we used rating
percentage. Statistical significance level was set to 5%.
RESULTS
The average UPDRS III scores in the OFF/OFF state, a surrogate
measure of the untreated severity of PD, were higher in the long-
termDBS group (46 vs. 38 in the short-termDBS group) although
this difference did not reach statistical significance (Table 1).
In the ON/OFF state, short-term DBS subjects showed
significant improvement in response to stimulation in all of the
measures examined with the exception of two walking tests: usual
speed walking and the SWS test (Tables 1, 2). Long-term DBS
subjects also showed significant improvement in the total UPDRS
III score, tremor, rigidity, bradykinesia, and GABS II; however,
gait, PIGD, and all the timed walking tests failed to improve with
stimulation (Tables 1, 2).
In the ON/ON state, short-term DBS subjects showed
further significant improvement in response to stimulation in
all measured parameters except for the SWS test. The long-
term DBS group improved significantly in the total UPDRS III
score, rigidity, and bradykinesia. No significant improvement
was noted in tremor, PIGD, or GABS parameters. The UPDRS
III gait subscore remained unaffected, and the outcome of
all quantitative walking tests showed worsening although the
differences were not significant. The difference in percentage
improvement between the short- and long-term DBS groups in
the ON/ON vs. OFF stim/ON med state was even more striking.
The PIGD score improved by 29.7% in the short-termDBS group
as compared with 12.3% in the long-term DBS group. Similarly,
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TABLE 1 | The mean values of UPDRS III and GABS II in all four states (stim/med) in patients with short and long-term stimulation (P-value).
Items Tremor Rigidity Brady Gait PIGD UPDRS III. GABS II.








Short-term DBS OFF stim 4.6 8.9 12.5 1.5 4.6 38.0 16.3
Short-term DBS ON stim 0.9 6.4 8.9 0.9 3.3 23.8 9.3
P-value On stim vs. Off stim 0.05 0.01 0.04 0.01 <0.01 0.002 <0.001
Long-term DBS OFF stim 3.2 8.7 19.3 2.0 6.5 46.0 25.1
Long-term DBS ON stim 0.3 4.7 11.6 1.8 5.7 28.3 21.3






Short-term DBS OFF stim 2.1 5.0 8.4 0.9 2.4 22.4 7.0
Short-term DBS ON stim 0.3 2.4 4.8 0.3 1.0 10.8 4.6
P-value ON stim vs. OFF stim 0.08 <0.01 <0.01 <0.05 0.01 <0.01 <0.05
Long-term DBS OFF stim 0.9 4.7 12.1 1.3 5.1 29.2 17.8
Long-term DBS ON stim 0.1 1.8 6.8 1.3 3.9 16.0 15.1
P-value ON stim vs. OFF stim 0.12 0.003 0.002 1.0 <0.01 0.002 0.16
PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale; DBS, Deep Brain Stimulation; GABS, Gait and Balance Scale; PIGD, Postural instability and gait disorders.
TABLE 2 | Timed gait tasks (GABS III) in all four states in PD patients with short- and long-term stimulation (P-value).








Short-term DBS OFF stim 20.8 16.1 18.4
Short-term DBS ON stim 18.3 14.1 18.4
P-value ON stim vs. OFF stim 0.15 <0.001 0.99
Long-term DBS OFF stim 27.9 24.3 39.0
Long-term DBS ON stim 25.7 22.9 29.8






Short-term DBS OFF stim 19.5 15.1 17.5
Short-term DBS ON stim 17.1 14.2 17.1
P-value ON stim vs. OFF stim <0.01 0.05 0.42
Long-term DBS OFF stim 22.2 19.5 24.6
Long-term DBS ON stim 23.2 19.8 28.9
P-value ON stim vs. OFF stim 0.48 0.71 0.46
PD, Parkinson’s disease; GABS, Gait and Balance Scale; SWS, Stand-walk-sit test; DBS, Deep Brain Stimulation.
GABS objective parameters improved 43% in the short-termDBS
group as compared with 15% in the long-termDBS group; for gait
rating, the difference was 70 vs. 0% (Table 3).
DBS and medications equally ameliorated UPDRS III total
scores in the short- and long-term DBS patients (Figure 1).
However, although both stimulation andmedication had positive
effects on the PIGD subscore in the short-term DBS group,
only medication improved PIGD in long-term DBS patients by
a minimal margin (Figure 2).
DISCUSSION
The results of this study confirm that short-term stimulation
(1–2 years) has a positive effect on all PD symptoms, including
balance and gait dysfunction. However, we observed a significant
decline of the beneficial effects of STN DBS in patients
treated for 5 years or more. In particular, gait and postural
disability appeared to specifically deteriorate, and DBS effects
on the other cardinal symptoms of PD remained robust. The
effects of dopaminergic medications were relatively preserved
in patients with long-term STN DBS, albeit to a lesser
degree as compared with those observed in the short-term
DBS group.
The observation of a decline of DBS efficacy on specific
features of PD over time is not new and has been generally
attributed to the unavoidable progression of axial symptoms
as part of the natural course of PD (1, 3, 4, 20, 21). To test
whether the declining benefits of DBS can be purely attributed
to the progression of the disease, we compared DBS responses
to the OFF condition at the follow-up visit as opposed to
presurgical or baseline OFF. We hypothesized that, despite the
predictable worsening of the OFF medication scores caused by
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TABLE 3 | Percentage change (decrease) of UPDRS III and GABS II scores after turning stimulation ON in PD patients with short- and long-term stimulation.








Short-term DBS 81.0 28.2 29.0 41.7 29.7 37.5 43.1






Short-term DBS 86.5 52.5 43.6 70.0 58.8 52.1 33.9
Long-term DBS 89.9 61.7 43.8 0 23.5 45.2 15.2
UPDRS, Unified Parkinson’s Disease Rating Scale; GABS, Gait and Balance Scale; PD, Parkinson’s disease; DBS, Deep Brain Stimulation; PIGD, Postural instability and gait disorders.
FIGURE 1 | The effect of medication and stimulation on UPDRS III in patients with short- and long-term DBS. UPDRS, The Unified Parkinson’s Disease Rating Scale;
DBS, Deep Brain Stimulation.
the progression of the disease, DBS improvement should have
been percentage-wise similar over time. As expected, we found
that the UPDRS III score in the OFF/OFF condition was ∼20%
higher in the long-term DBS group, which included chronically
stimulated patients with longer disease duration. Supporting the
hypothesis of a consistent DBS effect over time, both groups
showed a 38% average UPDRS III score improvement after DBS
was switched ON. However, the percentage improvement of
gait and balance functions (UPDRS items 27–31) dropped from
43% in short-term stimulation patients to 10% in their chronic
DBS counterparts. In addition, no gait improvement was found
in chronically stimulated patients in the ON/ON state. These
results were confirmed using more sensitive gait and balance
tests, providing further support to our analysis. Interestingly,
UPDRS item 29 best correlated with the timed tests measuring
walking as quickly as possible, and SWS and timed walking at
usual speed did not. The difference could lie in the fact that
the SWS test does not evaluate only gait and test of walking
by usual speed tends to be slower regardless of the ability to
walk faster in a given time. In conclusion, the decline of the
DBS effect observed in PD patients with chronic DBS may not
be only attributed to a natural progression of PD symptoms. A
declining ability of DBS to improve axial symptoms, including
gait and balance difficulties, seems to also play a specific role
(22). This could be due to either the progressive “intrusion”
of non-dopaminergic mechanisms (not responsive to DBS) in
the PIGD pathogenesis (27) or a progressively deleterious effect
of high-frequency stimulation on gait function. The residual,
milder improvement observed with levodopa would support
the first explanation. On the other hand, the reported benefit
of switching stimulation to lower frequencies after 5 years of
STN DBS (13) supports, at least in part, the second hypothesis.
Moreover, a review of the low-frequency effect DBS on axial
signs assumes that low frequency might be clinically useful
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FIGURE 2 | The effect of medication and stimulation on PIGD (items 27–30 of UPDRS) in patients with short- and long-term DBS. PIGD, Postural instability and gait
disorders; PD, Parkinson’s disease; UPDRS, The Unified Parkinson’s Disease Rating Scale; DBS, Deep Brain Stimulation; GABS, Gait and Balance Scale.
mainly when it lessens the detrimental effects of high-frequency
stimulation (28). In addition, DBS and levodopa might have a
different synergic effect on (29) cardinal symptoms in contrast
to gait disorders.
The main limitation of this study is the small number
of patients who were not followed prospectively. Although
the groups were comparable in age, time of disease duration,
and duration of the disease at the time of stimulation,
there might be an impact of interpatient variability on
observed results. Further prospective studies with a more
detailed analysis of gait parameters in larger cohorts of
chronically stimulated patients are needed to clarify this
crucial issue.
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